UK Markets closed

Kiromic BioPharma, Inc. (KRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2614-0.0026 (-0.98%)
At close: 03:35PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) -0.26
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 32.3800
52-week low 30.2300
50-day moving average 30.2959
200-day moving average 30.4662

Share statistics

Avg vol (3-month) 3664.19k
Avg vol (10-day) 364.29k
Shares outstanding 515.44M
Implied shares outstanding 6N/A
Float 811.46M
% held by insiders 117.21%
% held by institutions 16.81%
Shares short (13 Oct 2022) 4603.39k
Short ratio (13 Oct 2022) 40.36
Short % of float (13 Oct 2022) 43.94%
Short % of shares outstanding (13 Oct 2022) 43.81%
Shares short (prior month 14 Sept 2022) 4497.41k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-154.93%
Return on equity (ttm)-391.06%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -31.32M
Net income avi to common (ttm)-32.91M
Diluted EPS (ttm)-2.2410
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)6.51M
Total cash per share (mrq)0.41
Total debt (mrq)2.42M
Total debt/equity (mrq)20.55
Current ratio (mrq)1.35
Book value per share (mrq)0.66

Cash flow statement

Operating cash flow (ttm)-27.53M
Levered free cash flow (ttm)-20.52M